Coronavirus Outbreak: Goa-based drug maker GAPL eyes to get licence to produce hydroxychloroquine sulfate
GAPL is a subsidiary of HLL Lifecare Limited under the administrative control of Union ministry of health and family welfare. The company has a manufacturing facility at Tuem in North Goa.


Representational image. Reuters.[/caption]GAPL is a subsidiary of HLL Lifecare Limited under the administrative control of Union ministry of health and family welfare. The company has a manufacturing facility at Tuem in North Goa."The company has a licence to produce chloroquine sulfate (not hydroxychloroquine sulfate), but we have not produced it for the last 15 year. However, we have now decided to get licence for hydroxychloroquine sulfate considering the current demand," GAPL chief executive officer Reju Skaria said on Friday.He said that the company has been producing various pharmaceutical products depending upon the demand."We have the capacity to produce two crore tablets per month. We can utilise this capacity to produce any pharmaceutical product, for which we have a licence," he said.Skaria stated that there are difficulties in availability and transporting the Active Pharmaceutical Ingredient (API) required for the formations due to current lockdown.

Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge
Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs
Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key
Organ donation: 5 myths you need to stop believing, according to a transplant specialist
Fish over meat: Why a pescatarian diet may help people with obesity live longer
